Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes

Background. The purpose of this study was to determine the cellular effectors of both the adoptively transferred cells and the tumor-bearing host that participate in the antitumor response to adoptive immunotherapy using culture-activated tumor-draining lymph nodes (TDLNs). Methods. TDLNs harvested...

Full description

Saved in:
Bibliographic Details
Main Authors: John Ammori, Khaled Hamzeh, Hallie Graor, Julian Kim
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2015/170852
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552519570554880
author John Ammori
Khaled Hamzeh
Hallie Graor
Julian Kim
author_facet John Ammori
Khaled Hamzeh
Hallie Graor
Julian Kim
author_sort John Ammori
collection DOAJ
description Background. The purpose of this study was to determine the cellular effectors of both the adoptively transferred cells and the tumor-bearing host that participate in the antitumor response to adoptive immunotherapy using culture-activated tumor-draining lymph nodes (TDLNs). Methods. TDLNs harvested from mice with 4T1 carcinoma cells were fractionated to derive the L-selectinlow subpopulation and activated ex vivo prior to in vitro cytokine release assays and adoptive transfer into BALB/c mice bearing 3-day established subcutaneous tumors. Tumor-bearing recipients were SCID (lacking T, B, and NK cells), Rag2 deficient (lacking T and B cells), and wild-type BALB/c mice. Results. Culture-activated L-selectinlow 4T1 TDLN from BALB/c mice secreted significant levels of interferon-gamma in response to 4T1 but not control tumor cells in vitro. CD4 cells within the adoptively transferred effector cell population contributed significantly to the antitumor effect in vivo. Culture-activated L-selectinlow TDLNs from BALB/c wild-type mice were able to cure Rag2 deficient but not SCID mice bearing 4T1 subcutaneous tumors, suggesting a requirement of NK cells within the innate immune system of the tumor-bearing host during the antitumor response. Conclusions. These results identify the cellular effectors involved in tumor regression following adoptive transfer and demonstrate the requirement for intact innate immunity within the tumor-bearing host.
format Article
id doaj-art-9a3de18fc0514aa995e14ab2543db779
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-9a3de18fc0514aa995e14ab2543db7792025-02-03T05:58:26ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/170852170852Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph NodesJohn Ammori0Khaled Hamzeh1Hallie Graor2Julian Kim3Division of Surgical Oncology, Department of Surgery, University Hospitals Case Medical Center and Case Comprehensive Cancer Center, Cleveland, OH 44106, USADivision of Surgical Oncology, Department of Surgery, University Hospitals Case Medical Center and Case Comprehensive Cancer Center, Cleveland, OH 44106, USADivision of Surgical Oncology, Department of Surgery, University Hospitals Case Medical Center and Case Comprehensive Cancer Center, Cleveland, OH 44106, USADivision of Surgical Oncology, Department of Surgery, University Hospitals Case Medical Center and Case Comprehensive Cancer Center, Cleveland, OH 44106, USABackground. The purpose of this study was to determine the cellular effectors of both the adoptively transferred cells and the tumor-bearing host that participate in the antitumor response to adoptive immunotherapy using culture-activated tumor-draining lymph nodes (TDLNs). Methods. TDLNs harvested from mice with 4T1 carcinoma cells were fractionated to derive the L-selectinlow subpopulation and activated ex vivo prior to in vitro cytokine release assays and adoptive transfer into BALB/c mice bearing 3-day established subcutaneous tumors. Tumor-bearing recipients were SCID (lacking T, B, and NK cells), Rag2 deficient (lacking T and B cells), and wild-type BALB/c mice. Results. Culture-activated L-selectinlow 4T1 TDLN from BALB/c mice secreted significant levels of interferon-gamma in response to 4T1 but not control tumor cells in vitro. CD4 cells within the adoptively transferred effector cell population contributed significantly to the antitumor effect in vivo. Culture-activated L-selectinlow TDLNs from BALB/c wild-type mice were able to cure Rag2 deficient but not SCID mice bearing 4T1 subcutaneous tumors, suggesting a requirement of NK cells within the innate immune system of the tumor-bearing host during the antitumor response. Conclusions. These results identify the cellular effectors involved in tumor regression following adoptive transfer and demonstrate the requirement for intact innate immunity within the tumor-bearing host.http://dx.doi.org/10.1155/2015/170852
spellingShingle John Ammori
Khaled Hamzeh
Hallie Graor
Julian Kim
Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
Journal of Immunology Research
title Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
title_full Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
title_fullStr Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
title_full_unstemmed Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
title_short Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
title_sort requirement of innate immunity in tumor bearing mice cured by adoptive immunotherapy using tumor draining lymph nodes
url http://dx.doi.org/10.1155/2015/170852
work_keys_str_mv AT johnammori requirementofinnateimmunityintumorbearingmicecuredbyadoptiveimmunotherapyusingtumordraininglymphnodes
AT khaledhamzeh requirementofinnateimmunityintumorbearingmicecuredbyadoptiveimmunotherapyusingtumordraininglymphnodes
AT halliegraor requirementofinnateimmunityintumorbearingmicecuredbyadoptiveimmunotherapyusingtumordraininglymphnodes
AT juliankim requirementofinnateimmunityintumorbearingmicecuredbyadoptiveimmunotherapyusingtumordraininglymphnodes